During this sponsored webinar, we will overview Alzheimer's Disease (AD), discuss key considerations during the patient journey, and examine the potential impact of early intervention on the financial burden associated with AD.
Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up! sits down with Jennifer Graff, Senior Director of Professional Affairs at AMCP, to discuss trends to be watching regarding digital therapeutics and managed care pharmacy in 2023.
The Academy of Managed Care Pharmacy (AMCP) supports an abbreviated licensure pathway for the approval of biosimilar biologic drug therapies.
Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up!, sits down with Susan Cantrell, AMCP CEO, to discuss the significance of the recent passage of the Pre-approval Information Exchange (PIE) Act of 2022.
In the world of health care innovation, speed matters. But when it comes to developing and deploying cutting-edge treatments and therapeutics safely, a cautious and methodical approach is vital as well. Safety matters as much as speed, but faster doesn’t always mean riskier. In her latest blog, AMCP CEO Susan Cantrell discusses the history of the Pre-approval Information Exchange (PIE) Act and how it will help patients.
Andrey Ostrovsky, MD, FAAP, and Lisa Palko, PharmD, discuss the ADHD landscape, challenges, and progress, including Akili's digital therapeutics value proposition as the first FDA-authorized prescription video game treatment.
Partnership Forum: This forum helped identify payer needs and current barriers that payer currently face regarding evidence for therapies approved through an expedited approval process. In addition, participants identified potential solutions to address evidence gaps.
On today's episode of PopHealth Week, our guest is Eddie Martucci, PhD, co-founder & CEO of Akili Interactive, a company getting to the root of cognitive impairment by creating personalized digital therapeutics engineered to directly improve cognitive impairments.
Today, the Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) announced that it has received a major grant from the Food & Drug Administration (FDA) in support of biosimilars research. The award provides $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review.
In this August 2022 webinar, join AMCP Policy & Government Relations staff for an overview of federal legislation, federal regulation, state legislation, and the federal election outlook.
